New treatment may improve outcomes for patients with BRCA mutation-associated early breast cancer
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Titled Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer, the paper appears in the June 3 issue of the
Top cancer researchers convene in Beersheva
World-class experts from Israel and New York’s Memorial Sloan Kettering Cancer Center explore new frontiers in research and treatment.
Soroka Medical Center hosted the binational conference.
What are the connections between breast cancer and bone health, breast cancer and heredity, and obesity and cancer risk? Top Israeli and American experts gathered at Soroka Medical Center in Beersheva on April 2 to share new frontiers in cancer research and therapy that are changing our understanding of the disease dramatically.
The Israeli venue for a major meeting of medical minds was an obvious choice, according to conference co-chair Dr. Larry Norton, medical director of the Evelyn Lauder Breast Center at Memorial Sloan Kettering Cancer Center.